ARTICLE | Strategy
Isis executes
How new strategic partnership with AZ fits into Isis' partnering strategy
August 10, 2015 7:00 AM UTC
Isis Pharmaceuticals Inc. has planted a second pillar in its strategy of pursuing expansive long-term relationships that combine its antisense capabilities with the scientific and clinical expertise of its partners.
On Aug. 3, the company unveiled its second strategic partnership, under which Isis and AstraZeneca plc will work to discover and develop antisense therapeutics for cardiovascular, metabolic and renal diseases. The goal is to open new target space...